Chimeric Antigen Receptor-T Cell (CAR-T Cell) Therapy in Advanced Renal Cell Carcinoma
Published: 2021-05-17
Page: 127-135
Issue: 2021 - Volume 4 [Issue 1]
Brian Mark Churchill *
Medical Science and Strategy (Asia), IQVIA, Omega, Embassy Tech Square, Marathahalli- Sarjapur Outer Ring Road, Kadubeesanahalli, Bengaluru, Karnataka, 560103, India.
Pallavi Patri
Department of Nephrology, Columbia Asia Hospital – Sarjapur Road, Ambalipura, Bengaluru, Karnataka, 560102, India and Faculty, Weill Cornell Medical College, New York, USA.
Jula K. Inrig
Therapeutic Science and Strategy Unit, IQVIA, 10188 Telesis Ct Suite 400, San Diego, CA 92121, USA and Faculty, Department of Medicine, UC Irvine and Duke University, USA.
Anju Gopan
Oncology/Haematology, Medical Science and Strategy (Asia), IQVIA, Omega, Embassy Tech Square, Marathahalli - Sarjapur Outer Ring Road, Kadubeesanahalli, Bengaluru, Karnataka, 560103, India.
Ekaterina Vorozheikina
Medical and Scientific Services, Hematology/Oncology, EU, IQVIA, Moscow, Russia.
Luis Mendoza
Senior Medical Advisor, Regional Team Head Hematology/Oncology, EU, Medical and Scientific Services, Prague, Czech Republic.
Lara Kristina Donato
Medical Oncology and Hematology (Asia), 8/201 Pacific Highway, St. Leonards, Sydney, NSW, 2065, Australia.
Ruma Pal Ghosh
Boston University School of Medicine, Boston, MA, USA.
*Author to whom correspondence should be addressed.
Abstract
With introduction of immunotherapy, the treatment of advanced renal cell carcinoma has undergone a substantial change. Immunotherapeutic agents including nivolumab, ipilimumab, pembrolizumab, have been introduced and approved for therapy of this life-threatening malignancy. Chimeric antigen receptor- T cells produced using adoptive cell transfer genetic engineering technology, have shown significant benefits over previous immunotherapies, but their toxicity profile needs to be carefully weighed. While they have shown significant benefit in hematological malignancies, their role in solid tumors has shown mixed results. Several clinical trials are ongoing to evaluate their safety and efficacy in several malignancies, including advanced renal cell carcinoma.
This paper reviews in brief the immunotherapy and CAR-T cell therapy in renal cell carcinoma.
Keywords: Chimeric antigen receptor, CAR-T cell therapy, renal cell carcinoma